- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Humanigen Inc.
Headquarters: Brisbane, CA, United States of America
Website: N/A
Year Founded: 2000
Status: Out of Business
BioCentury | Nov 14, 2022
Data Byte
A snapshot of the GM-CSF pipeline
GSK’s decision to drop otilimab brings other GM-CSF therapies under focus
BioCentury | Oct 25, 2022
Management Tracks
SK hires new head of vaccine R&D, clinical development
Plus Sutro’s CMO leaves and updates from Shoreline, Opthea and Aurinia
BioCentury | Oct 4, 2022
Management Tracks
Sause named CEO of Roche Diagnostics
Plus Kranzler becomes CEO of Urica, and updates from Pharus, Celularity, Cerevance and more
BioCentury | Jul 14, 2022
Finance
July 13 Quick Takes: Pliant raises $200M on back of positive data; CytomX restructuring
Plus ContraFect tumbles on exebacase setback, and updates from AgomAb, Xilis, and more
BioCentury | Sep 10, 2021
Product Development
Sept. 9 Quick Takes: Obsidian readies for IPO with $115M crossover round
Plus: Venture rounds for Lexeo, Evommune, Alamar, and setbacks for Humanigen, Sanofi and more
BioCentury | Apr 22, 2021
Management Tracks
Ceesay joins Coles’ Cerevel as president; plus updates from Replimune, Perceptive, Antiva, Vera, Patient Square, Zymeworks and more
BioCentury | Mar 29, 2021
Product Development
March 29 Quick Takes: Humanigen mAb meets COVID endpoint; plus Merck, Wave, Celldex, Ionis, Orphazyme and uniQure
Humanigen Inc. (NASDAQ:HGEN) shares rose 54% to $21.61 Monday after the company said top-line data showed lenzilumab improved survival without the need for mechanical ventilation in hospitalized
BioCentury | Oct 14, 2020
Product Development
A third leading COVID program enters holding pattern as NIH pauses testing of Lilly’s mAb
NIH begins ACTIV-5 study of anti-inflammatory mAbs, plus Moderna starts rolling submission in Canada
BioCentury | Sep 2, 2020
Product Development
COVID-19 Quick Takes: NAS framework on vaccine allocation prioritizes higher risk groups
Plus Soriot reiterates AZ’s commitment to ‘follow the science,’ deliver equitable access
BioCentury | Aug 25, 2020
Management Tracks
Former head of gRED Varney joining Erasca; plus AAM, City of Hope, Immunovant, Kura, Illumina and more
Former head of gRED Michael Varney is joining cancer company Erasca Inc. as chairman of R&D and a scientific advisory board member. Varney retired in July after 15 years at the
Items per page:
1 - 10 of 15